Table 1. Patients’ and treatment characteristics for overall group and matched group after propensity scoring.
| Variables | Overall Patients | Matched Patients | |||||
|---|---|---|---|---|---|---|---|
| Propofol (n = 266) | Desflurane (n = 365) | p value | Propofol (n = 264) | Desflurane (n = 264) | p value | SMD | |
| Time since the earliest included patient (years), Mean (SD) | 4.8 (2.4) | 5.3 (3.0) | 0.014 | 4.8 (2.4) | 4.3 (2.5) | 0.045 | 0.177 |
| Calendar period, n (%) | <0.001 | 0.080 | 0.133 | ||||
| 2009–12 | 92 (35) | 125 (34) | 92 (35) | 116 (44) | |||
| 2013–15 | 110 (41) | 97 (27) | 110 (42) | 89 (34) | |||
| 2016–18 | 64 (24) | 143 (39) | 62 (24) | 59 (22) | |||
| Age (yr), mean (SD) | 65.3 (6.5) | 66.4 (7.2) | 0.066 | 65.3 (6.5) | 66.3 (7.4) | 0.118 | 0.136 |
| PSA | 0.604 | 0.254 | 0.119 | ||||
| ≤ 10 | 143 (54) | 205 (56) | 141 (53) | 155 (59) | |||
| > 10 | 123 (46) | 160 (44) | 123 (47) | 109 (41) | |||
| Charlson comorbidity index, mean (SD) | 4.1 (0.70) | 4.2 (0.78) | 0.164 | 4.1 (0.70) | 4.2 (0.79) | 0.242 | 0.108 |
| Functional status, n (%) | 0.232 | 0.549 | 0.131 | ||||
| < 4 METs | 22 (8) | 42 (12) | 22 (8) | 27 (10) | |||
| ≥ 4 METs | 244 (92) | 323 (89) | 242 (92) | 234 (90) | |||
| ASA, n (%) | 0.232 | 0.549 | 0.131 | ||||
| Lower risk | 244 (92) | 323 (89) | 242 (92) | 234 (90) | |||
| Higher risk | 22 (8) | 42 (12) | 22 (8) | 27 (10) | |||
| TNM stage of primary tumor, n (%) | 0.563 | 0.045 | 0.173 | ||||
| I | 44 (17) | 65 (18) | 43 (16) | 51 (19) | |||
| II | 197 (75) | 274 (75) | 196 (74) | 202 (77) | |||
| III | 25 (9) | 26 (7) | 25 (10) | 11 (4) | |||
| Tumor grade (Gleason grade) | 0.145 | 0.178 | 0.011 | ||||
| Low risk (Gleason grade ≤ 6) | 36 (14) | 45 (12) | 34 (13) | 24 (9) | |||
| Medium risk (Gleason = 7) | 101 (38) | 167 (46) | 101 (38) | 119 (45) | |||
| High risk (Gleason > 7) | 129 (49) | 153 (42) | 129 (49) | 121 (46) | |||
| Tumor size (cm), mean (SD) | 1.6 (0.89) | 1.5 (0.83) | 0.169 | 1.6 (0.89) | 1.6 (0.87) | 0.419 | N/A |
| Intraoperative blood transfusion, n (%) | 10 (4) | 8 (2) | 0.354 | 10 (4) | 6 (2) | 0.446 | N/A |
| Grade of surgical complications, n (%) | 0.975 | 1.000 | N/A | ||||
| 0 | 257 (97) | 354 (97) | 255 (97) | 256 (97) | |||
| I + II | 9 (3) | 11 (3) | 9 (3) | 8 (3) | |||
| Postoperative radiation therapy, yes, n (%) | 32 (12) | 50 (14) | 0.620 | 32 (12) | 34 (13) | 0.895 | N/A |
| Postoperative ADT, yes, n (%) | 42 (16) | 55 (15) | 0.892 | 42 (16) | 46 (17) | 0.726 | N/A |
| Postoperative biochemical recurrence, n (%) | 2 (1) | 13 (4) | 0.043 | 2 (1) | 12 (5) | 0.015 | N/A |
| All-cause mortality, n (%) | 2 (1) | 24 (7) | 0.001 | 2 (1) | 21 (8) | <0.001 | N/A |
| Cancer mortality, n (%) | 0 (0) | 5 (1) | 0.073 | 0 (0) | 4 (2) | 0.055 | N/A |
PSA: prostate specific antigen; METs: Metabolic equivalents; ASA: American Society of Anesthesiologists; TNM: tumor-node-metastasis; ADT: androgen deprivation therapy; SMD: standardized mean differences; N/A: not applicable.